Phase 2 N=21 Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
Melanoma
Primary: Percentage of Participants Surviving at 1 Year — 66.7 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 PK Analysis of Piperacillin in Septic Shock Patients
Septic Shock
Primary: 100% f T>MIC: Free Piperacillin Concentration Maintained Above the MIC Throughout the Dosing Interval. — 10 participants
Phase 2 N=28 Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: Progression-free Survival (PFS) > 6 Months — 8.0 percentage of participants
Phase 2 N=403 Study of Long-Acting Acetaminophen in Postoperative Dental Pain
Dental Pain
Primary: Time Weighted Sum of Pain Intensity Difference (PID) Over 10 Hours (SPID 0-10) — 5.745; 30.986 units on a scale — p=<0.001
Phase 4 N=396 Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections
Skin Diseases, Infectious
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 36.1; 36.8; 23.3; 18.4 percentage of participants
N/A N=226 A Study of the Relief of Tooth Sensitivity of an Experimental Mouthrinse Device
Dentin Sensitivity
Primary: Mean Tactile Sensitivity Score at Week 4 — 10.39; 21.83; 18.72 grams of force — p=<0.001
Phase 2 N=131 A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
Primary: Progression-free Survival — 2.6; 2.9 months
Phase 2 N=36 Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
Malignant Ovarian Epithelial Tumor · Ovarian Granulosa Cell Tumor · Ovarian Gynandroblastoma
Primary: Tumor Response — 16.7 percentage of patients
N/A N=552 Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Incidence of Adverse Drug Reactions (ADRs) — 33.3 Percentage of participants
Phase 3 N=127 Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Anemia
Primary: Incidence of Treatment-emergent Adverse Events — 84 each event
Phase 2 N=21 Iron Sucrose In The Treatment of Restless Legs Syndrome: Safety of Three Dose Regimens as Evaluated by Clinical Assessments
Restless Legs Syndrome
Primary: Mean Change From Baseline to Day 84 for International Restless Leg Syndrome Study Group (IRLSSG) Scale — -2.4; -14.3; -16.0 units on a scale
N/A N=153 A Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity
Dentin Sensitivity
Primary: Mean Tactile Sensitivity Score at Week 4 — 11.21; 23.81; 22.07 grams of force — p=<0.001
Phase 4 N=107 Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients
Schizophrenia
Primary: Total Weeks Worked — 51.53; 41.37 Weeks — p=0.66
Phase 3 N=462 Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
Neurotoxicity · Pain · Peripheral Neuropathy
Primary: Change in Average Daily Peripheral Neuropathy Intensity Score From Baseline to Week 6 in Patients Treated With Amitriptyline and Ketamine Hydrochloride vs Placebo…
N/A N=28 Clinical Evaluation of Opti-Free III (FID 109182) Compared to Opti-Free Plus® in Japan
Corneal Staining
Primary: Proportion of Participants Scoring ≥ 2 for Corneal Staining Density With Fluorescein — 92.6; 22.2 percentage of participants